GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers

Pilar Nava-Parada, Leisha A. Emens

Research output: Contribution to journalReview articlepeer-review

Abstract

GemVax AS, a subsidiary of Pharmexa A/S, is developing GV-1001, an injectable formulation of a promiscuous MHCclass II peptide derived from the telomerase reverse transcriptase catalytic subunit (hTERT), for the potential treatment of solid tumors, including pancreatic, liver and NSCLC. GV-1001 is currently undergoing phase II clinical trials for pancreatic, liver and NSCLC as well as a phase III trial for pancreatic cancer.

Original languageEnglish (US)
Pages (from-to)490-497
Number of pages8
JournalCurrent Opinion in Molecular Therapeutics
Volume9
Issue number5
StatePublished - Oct 19 2007

ASJC Scopus subject areas

  • Molecular Medicine
  • Molecular Biology
  • Genetics
  • Pharmacology
  • Drug Discovery
  • Genetics(clinical)

Fingerprint Dive into the research topics of 'GV-1001, an injectable telomerase peptide vaccine for the treatment of solid cancers'. Together they form a unique fingerprint.

Cite this